Skip to main content

Clinical trial EPIK-B5

EPIK-B5: A Phase III, randomized, double-blind, placebocontrolled study of alpelisib (BYL719) in combination with fulvestrant for men and postmenopausal women with HRpositive, HER2-negative advanced breast cancer with a PIK3CA mutation, who progressed on or after aromatase inhibitor and a CDK4/6 inhibitor

Cancers
Organ Breast
Trial status Trial open for recruitment
Investigator
Trial type
Interventional with experimental drug
Phase Trial phase 3
Academic trial Non
Sponsor Novartis
EudraCT Identifier 2021-001966-39
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT05038735
Last update